Tags

Type your tag names separated by a space and hit enter

Humoral immune responses to influenza vaccination in patients with obstructive sleep apnea.

Abstract

STUDY OBJECTIVE

To compare humoral immune responses to influenza vaccination in subjects with obstructive sleep apnea (OSA) and in healthy volunteers (control subjects).

DESIGN

Prospective, controlled, parallel-design study.

SETTING

Sleep disorders center at a university hospital.

SUBJECTS

Fourteen untreated subjects with moderate-to-severe OSA (apnea hypopnea index > 15 events/hr) and 17 healthy volunteers (control subjects).

INTERVENTION

All subjects were given the influenza vaccine for the years 2004-2005 or 2005-2006.

MEASUREMENTS AND MAIN RESULTS

Blood samples were obtained before and 2-4 weeks after vaccination to measure serum antibody titers for the A/New Caledonia/20/99 (H1N1)-like and B/Shanghai/361/2002-like viral strains by using the hemagglutination inhibition assay. Seroconversion was defined as an increase in the antibody titer by more than 4-fold, whereas seroprotection was defined as an antibody titer greater than 40 hemagglutination units. The mean +/- standard error of the mean apnea hypopnea index, calculated as the number of abnormal respiratory events divided by the number of hours of total sleep time, was 56 +/- 12 events/hour in the OSA group and 1.0 +/- 0.4 oxygen desaturations/hour in the control group (p<0.05). However, no significant differences were observed in changes in antibody concentration, frequencies of seroconversion, or rates of seroprotection between subjects with OSA and control subjects. Polysomnographic measures of OSA were not correlated with immune responses.

CONCLUSION

Although pathophysiologic characteristics of OSA may influence immune responses, moderate-to-severe OSA did not impair humoral responses to the influenza vaccine in these subjects.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA. jmdopp@pharmacy.wisc.edu

    , , , ,

    Source

    Pharmacotherapy 27:11 2007 Nov pg 1483-9

    MeSH

    Adult
    Antibodies, Viral
    Antibody Formation
    Female
    Hemagglutination Inhibition Tests
    Humans
    Influenza A Virus, H1N1 Subtype
    Influenza B virus
    Influenza Vaccines
    Male
    Middle Aged
    Polysomnography
    Prospective Studies
    Sleep Apnea, Obstructive
    Sleep Deprivation

    Pub Type(s)

    Controlled Clinical Trial
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    17963457

    Citation

    Dopp, John M., et al. "Humoral Immune Responses to Influenza Vaccination in Patients With Obstructive Sleep Apnea." Pharmacotherapy, vol. 27, no. 11, 2007, pp. 1483-9.
    Dopp JM, Wiegert NA, Moran JJ, et al. Humoral immune responses to influenza vaccination in patients with obstructive sleep apnea. Pharmacotherapy. 2007;27(11):1483-9.
    Dopp, J. M., Wiegert, N. A., Moran, J. J., Muller, D., Weber, S., & Hayney, M. S. (2007). Humoral immune responses to influenza vaccination in patients with obstructive sleep apnea. Pharmacotherapy, 27(11), pp. 1483-9.
    Dopp JM, et al. Humoral Immune Responses to Influenza Vaccination in Patients With Obstructive Sleep Apnea. Pharmacotherapy. 2007;27(11):1483-9. PubMed PMID: 17963457.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Humoral immune responses to influenza vaccination in patients with obstructive sleep apnea. AU - Dopp,John M, AU - Wiegert,Nicholas A, AU - Moran,John J, AU - Muller,Daniel, AU - Weber,Steven, AU - Hayney,Mary S, PY - 2007/10/30/pubmed PY - 2007/12/21/medline PY - 2007/10/30/entrez SP - 1483 EP - 9 JF - Pharmacotherapy JO - Pharmacotherapy VL - 27 IS - 11 N2 - STUDY OBJECTIVE: To compare humoral immune responses to influenza vaccination in subjects with obstructive sleep apnea (OSA) and in healthy volunteers (control subjects). DESIGN: Prospective, controlled, parallel-design study. SETTING: Sleep disorders center at a university hospital. SUBJECTS: Fourteen untreated subjects with moderate-to-severe OSA (apnea hypopnea index > 15 events/hr) and 17 healthy volunteers (control subjects). INTERVENTION: All subjects were given the influenza vaccine for the years 2004-2005 or 2005-2006. MEASUREMENTS AND MAIN RESULTS: Blood samples were obtained before and 2-4 weeks after vaccination to measure serum antibody titers for the A/New Caledonia/20/99 (H1N1)-like and B/Shanghai/361/2002-like viral strains by using the hemagglutination inhibition assay. Seroconversion was defined as an increase in the antibody titer by more than 4-fold, whereas seroprotection was defined as an antibody titer greater than 40 hemagglutination units. The mean +/- standard error of the mean apnea hypopnea index, calculated as the number of abnormal respiratory events divided by the number of hours of total sleep time, was 56 +/- 12 events/hour in the OSA group and 1.0 +/- 0.4 oxygen desaturations/hour in the control group (p<0.05). However, no significant differences were observed in changes in antibody concentration, frequencies of seroconversion, or rates of seroprotection between subjects with OSA and control subjects. Polysomnographic measures of OSA were not correlated with immune responses. CONCLUSION: Although pathophysiologic characteristics of OSA may influence immune responses, moderate-to-severe OSA did not impair humoral responses to the influenza vaccine in these subjects. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/17963457/Humoral_immune_responses_to_influenza_vaccination_in_patients_with_obstructive_sleep_apnea_ L2 - https://doi.org/10.1592/phco.27.11.1483 DB - PRIME DP - Unbound Medicine ER -